Quinoline antimalarials

Bibliography

• RIDLEY RG, HUDSON AT: Quinoline antimalarials. Exp. Opin. Thar. Patents (1998) 8:121–136.
   Web of Science ®Google Scholar
• World Health Organization report on infectious diseases, removing obstacles to healthy development. WHO, Geneva (1999).
   Google Scholar
• TRIGG PI, KONDRACHINE AV: The current global malaria situation. In: Malaria. Parasite biology, pathogenesis and protection. Sherman IW (Ed.), ASM Press, Washington DC (1998):11–22.
   Google Scholar
• LINDSAY SW, MARTENS WJ: Malaria in the African highlands: past, present and future. Bull. World Health Organ. (1998) 76:33–45.
   PubMed Web of Science ®Google Scholar
• BROOKE BD, HUNT RH, COETZEE M: Resistance to dieldrin + fipronil assorts with chromosome inversion 2La in the malaria vector Anopheles gambiae. Med. Vet. Entomol. (2000) 14:190–194.
   PubMed Web of Science ®Google Scholar
• MAKONO R, SIBANDA S: Review of the prevalence of malaria in Zimbabwe with specific reference to parasite drug resistance (1984-96). Trans. R. Soc. Trop. Med. Hyg. (1999) 93:449–452.
   PubMed Web of Science ®Google Scholar
• BARAT LM, BLOLAND PB: Drug resistance among malaria and other parasites. Infect. Dis. Clin. North. Am. (1997) 11:969–987.
   PubMed Web of Science ®Google Scholar
• SCHLAGENHAUF P: Mefloquine for malaria chemopro-phylaxis 1992-1998: a review. J. Travel Med. (1999) 6:122–133.
   PubMed Web of Science ®Google Scholar
• WHITE NJ: Why is it that antimalarial drug treatmentsdo not always work? Ann. Trop. Med. Parasitol (1998) 92:449–458.
   Google Scholar
• WERNSDORFER WH, MCGREGOR I: Malaria: principles and practice of malariology. Churchill-Livingstone, Edinburgh (1988).
   Google Scholar
• RUDZINSKA MA, TRAGER W, BRAY RS: Pinocytic uptake and digestion of haemoglobin in malaria parasites. J. Protozool. (1965) 12:563–576.
   PubMedGoogle Scholar
• FRANCIS SE, SULLIVAN DJ, GOLDBERG DE: Haemoglobin metabolism in the malaria parasite Plasmodium falciparum. Ann. Rev. Microbiol. (1997) 51:97–123.
   PubMed Web of Science ®Google Scholar
• TYAS L, MOON RP, LOETSCHER H et al.: Plasmepsinsand II from the malarial parasite Plasmodium falciparum. Adv. Exp. Med. Biol. (1998) 436:407–411.
   PubMed Web of Science ®Google Scholar
• ORJIH AU, BANYAL HS, CHEVLI R, FITCH CD: Haemin lyses malaria parasites. Science (1981) 214:667–669.
   PubMed Web of Science ®Google Scholar
• LADAN H, NITZAN Y, MALIK Z: The antibacterial activity of haemin compared with cobalt, zinc and magnesium protoporphyrin and its effect on potassium loss and ultrastructure of Staphylococcus aureus. FEMS Microbiol. Lett. (1993) 112:173–178.
   PubMed Web of Science ®Google Scholar
• PAGOLA S, STEPHENS PW, BOHLE DS, KOSAR AD, MADSEN SK: The structure of malaria pigment (I3-haematin). Nature (2000) 404:307–310.
   PubMed Web of Science ®Google Scholar
• •This paper reports the crystal structure of haemozoin.
   Google Scholar
• BOHLE DS, DINNEBIER RE, MADSEN SK, STEPHENS PW: Characterization of the products of the haem detoxifi-cation pathway in malarial late trophozoites by x-ray diffraction. J. Biol. Chem. (1997) 272:713–716.
   PubMed Web of Science ®Google Scholar
• SLATER AFG, SWIGGARD WJ, ORTON BR et al.: An iron-carboxylate bond links the haem units of malaria pigment. Proc. Natl. Acad. Sci. USA (1991) 88:325–329.
   PubMed Web of Science ®Google Scholar
• SLATER AFG, CERAMI A: Inhibition by chloroquine of anovel haem polymerase enzyme activity in malaria trophozoites. Nature (1992) 355:167–169.
   PubMed Web of Science ®Google Scholar
• •The original paper showing that chloroquine inhibits I3-haematin formation. At the time it was assumed that the drug inhibited an enzyme responsible for haemozoin formation.
   Google Scholar
• CHOU AC, FITCH CD: Haem polymerase. Modulation by chloroquine treatment of a rodent malaria. Life Sci. (1992) 51:2073–2078.
   Google Scholar
• CHOU AC, FITCH CD: Control of haem polymerase by chloroquine and other quinoline derivatives. Biochem. Biophys. Res. Commun. (1993) 195:422–427.
   PubMed Web of Science ®Google Scholar
• DORN A, STOFFEL R, MATILE H, BUBENDORF A, RIDLEY RG: Malarial haemozoin/13-haematin supports haem polymerisation in the absence of protein. Nature (1995) 374:269–271.
   PubMed Web of Science ®Google Scholar
• DORN A, VIPPAGUNTA SR, MATILE H, BUBENDORF A, VENNERSTROM JL, RIDLEY RG: A comparison and analysis of several ways to promote haematin (haem) polymerisation and an assessment of its initiation in vitro. Biochem. Pharmacol. (1998) 55:737–747.
   PubMed Web of Science ®Google Scholar
• BENDRAT K, BERGER BJ, CERAMI A: Haem polymerisa-tion in malaria. Nature (1995) 378:138 (letter).
   Google Scholar
• RIDLEY RG, DORN A, MATILE H, KANSY M: Haem polymerisation in malaria. Nature (1995) 378:138-139 (reply).
   Google Scholar
• SULLIVAN DJ, GLUZMAN IY, GOLDBERG DE: Plasmo-dium haemozoin formation mediated by histidine-rich proteins. Science (1996) 271:219–222.
   PubMed Web of Science ®Google Scholar
• LYNN A, CHANDRA S, MALHOTRA P, CHAUHAN VS: Haem binding and polymerisation by Plasmodium falciparum histidine rich protein II: influence of pH on activity and conformation. FEBS Lett (1999) 459:267–271.
   PubMed Web of Science ®Google Scholar
• CHOI CYH, CERDA JF, CHU H-A, BABCOCK GT, MARLETTA MA: Spectroscopic characterization of the haem-binding sites in Plasmodium falciparum histidine-rich protein 2. Biochemistry (1999) 38:16916–16924.
   PubMed Web of Science ®Google Scholar
• EGAN TJ, MAVUSO WW, NCOKAZI KK: The mechanism of 13-haematin formation in acetate solution. Parallels between haemozoin formation and biomineralisation processes. Biochemistry (2001) 40:204–213.
   Google Scholar
• BLACK RH, CANFIELD CJ, CLYDE DF, PETERS W, WERNSDORFER WH: In: Chemotherapy of malaria. Bruce-Chwatt LJ (Ed.), WHO, Geneva (1981).
   Google Scholar
• WINSTANLEY PA, BRECKENRIDGE AM: Currently important antimalarial drugs. Ann. Trop. Med. Parasitol. (1987) 81:619–627.
   PubMed Web of Science ®Google Scholar
• HAWLEY SR, BRAY PG, MUNGTHIN M, ATKINSON JD, O'NEILL PM, WARD SA: Relationship between antima-larial drug activity, accumulation and inhibition of haem polymerisation in Plasmodium falciparum in vitro. Antimicr. Agents Chemother. (1998) 42:682–686.
   PubMed Web of Science ®Google Scholar
• •Evidence is reported in this paper which indicates that antiplasmodial activity is correlated with I3-haematin inhibi-tory potency of drugs, provided antiplasmodial activity is normalised to account for different extents of cellular accumulation. Also reports activity of desethyl chloroquine and amodiaquine metabolites and a large range of drugs against a series of chloroquine sensitive and resistant strains.
   Google Scholar
• BRAY PG, HAWLEY SR, WARD SA: 4-Arninoquinoline resistance of Plasmodium falciparum: insights from the study of amodiaquine uptake. Mol Pharmacol (1996) 50:1551–1558.
   PubMed Web of Science ®Google Scholar
• MULLER 0, VAN HENSBROEK MB, JAFFAR S et al.: A randomised trial of chloroquine, amodiaquine and pyrimethamine-sulfadoxine in Gambian children with uncomplicated malaria. Trop. Med. Int. Health (1996) 1:124–132.
   Google Scholar
• HATTON CS, PETO TE, BUNCH C et al.: Frequency of severe neutropenia associated with amodiaquine prophylaxis against malaria. Lancet (1986) 1:411–413.
   PubMed Web of Science ®Google Scholar
• TINGLE MD, JEWELL H, MAGGS JL, O'NEILL PM, PARK BK: The bioactivation of amodiaquine by human p olymor-phonuclear leukocytes in vitro: chemical mechanisms and the effects of fluorine substitution. Biochem. Pharmacol. (1995) 50:1113–1119.
   PubMed Web of Science ®Google Scholar
• NAISBITT DJ, RUSCOE JE, WILLIAMS DP, O'NEILL PM, PIRMOHAMED M, PARK BK: Disposition of amodia-quine and related antimalarial agents in human neutrophils: implications for drug design. J. Pharm. Exp. Thar. (1997) 280:884–893.
   PubMed Web of Science ®Google Scholar
• NAISBITT DJ, WILLIAMS DP, O'NEILL PM, MAGGS JL, WILLOCK DJ, PIRMOHAMED M, PARK BK: Metabolism-dependent neutrophil cytotoxicity of amodiaquine: a comparison with pyronaridine and related antima-larial drugs. Chem. Res. Toxicol (1998) 11:1586–1595.
   PubMed Web of Science ®Google Scholar
• •This paper reports biochemical evidence that suggests pyronaridine could potentially cause agranulocytosis.
   Google Scholar
• RUSCOE JE, TINGLE MD, O'NEILL PM, WARD SA, PARK BK: Effect of dip osition of Mannich antimalarial agents on their pharmacology and toxicology. Antimicr. Agents Chemother. (1998) 42:2410–2416.
   PubMed Web of Science ®Google Scholar
• DOUER D, SCHWARTZ E, SHAKED N, RAMOT B: Amodiaquine-induced agranulocytosis: drug inhibi-tion of myeloid colonies in the presence of patients' serum. Israeli Med. Sci (1985) 21:331–333.
   PubMedGoogle Scholar
• RHODES EG, BALL J, FRANKLIN IM: Arnodiaquine-induced agranulocytosis: inhibition of colony growth in bone marrow by antimalarial agents. Br. Med. J. (1986) 292:717–718.
   PubMed Web of Science ®Google Scholar
• NEFTEL KA, WOODTLY W, SCHMID M, FRICK PG, FEHR J: Amodiaquine induced agranulo cy to sis and liver damage. Br Med. J. (1986) 292:721–723.
   PubMed Web of Science ®Google Scholar
• OLLIARO P, NEVILL C, LE BRAS J, RING WALD P, MUSSANO P, GARNER P, BRASSEUR P: Systematic review of amodiaquine treatment in uncomplicated malaria. Lancet (1996) 348:1196–1201.
   PubMed Web of Science ®Google Scholar
• OLLIARO P, MUSSANO P: Arnodiaquine for treating malaria. Cochrane Database Syst. Rev. (2000) CD000016.
   Google Scholar
• WINSTANLEY P, EDWARDS G, ORME M, BRECKENRIDGE A: The disposition of amodiaquine in man after oral administration. Br. J. Clin. Pharmacol. (1987) 23:1–7.
   PubMed Web of Science ®Google Scholar
• WHITE NJ, LOOAREESUWAN S, WARRELL DA, CHONGSUPHAJAISIDDHI T, BUNNAG D, HARINASUTA T: Quinidine in falciparum malaria. Lancet (1981) 2:1069–1071.
   PubMed Web of Science ®Google Scholar
• PRICE RN, CASSAR C, BROCKMAN A et al.: The pfmdrlgene is associated with a multidrug-resistant © Ashley Publications Ltd. All rights reserved.Exp. Opin. Ther. Patents (2001) 11(2) phenotype in Plasmodium falciparum from the western border of Thailand. Antimicr. Agents Chemother. (1999) 43:2943–2949.
   Google Scholar
• ••This paper reports evidence for multi-drug resistant parasitestrains with resistance to mefloquine, quinine, halofantrine and with reduced sensitivity to artesunate linked to multi-drug resistance gene.
   Google Scholar
• NEWTON P, KEERATITHAKUL D, TEJA-ISAVADHARM P, PUKRITTAYAKAMEE S, KYLE DE, WHITE NJ: Pharma-cokinetics of quinine and 3-hydroxyquinine in severe falciparum malaria with acute renal failure. Trans. R. Soc. Trop. Med. Hyg. (1999) 93:69–72.
   PubMedGoogle Scholar
• NOSTEN F, TER KUILE FO, CHONGSUPHAJAISIDDHI T et Mefloquine-resistant falciparum malaria on the Thai-Burmese border. Lancet (1991) 337:1140–1143.
   PubMed Web of Science ®Google Scholar
• VENNERSTROM JL, NUZUM EO, MILLER RE et al.: 8-Aminoquinolines active against blood stage Plasmo-dium falciparum in vitro inhibit haematin polymeri-sation. Antimicr. Agents Chemother. (1999) 43:598–602.
   PubMed Web of Science ®Google Scholar
• ••This paper reports on novel 8-aminoquinolines withrelatively strong blood-stage activity and with evidence suggesting a possibly similar mechanism of action to chloroquine.
   Google Scholar
• SMOAK BL, DE FRAITES RF, MAGILL AJ, KAIN KC, WELLDE BT: Plasmodium vivax infections in US Army troops: failure of primaquine to prevent relapse in studies from Somalia. Am. J. Trop. Med. Hyg. (1997) 56:231–234.
   PubMed Web of Science ®Google Scholar
• COLLINS WE, JEFFERY GM: Primaquine resistance in Plasmodium vivax. Am. J. Trop. Med. Hyg. (1996) 55:243–249.
   PubMed Web of Science ®Google Scholar
• FU S, XIAO SX: Pyronaridine: a new antimalarial drug. Parasitol. Today (1991) 7:310–313.
   PubMedGoogle Scholar
• RINGWALD P, BICKII J, BASCO L: Randomised trial of pyronaridine versus chloroquine for acute uncompli-cated falciparum malaria in Africa. Lancet (1996) 347:24–28.
   PubMed Web of Science ®Google Scholar
• LOOAREESUWAN S, KYLE DE, VIRAVAN C, VANIJAN-ONTA S, WILAIRATANA P, WERNSDORFER WH: Clinical study of pyronaridine for the treatment of acute uncomplicated falciparum malaria in Thailand. Am. J Trop. Med. Hyg. (1996) 54:205–209.
   PubMed Web of Science ®Google Scholar
• RINGWALD P, BICKII J, BASCO L: Efficacy of oral pyronaridine for the treatment of acute uncompli-cated falciparum malaria in African children. Clin. Infect. Dis. (1998) 2 6 :946–953.
   Google Scholar
• PETERS W, ROBINSON BL: The chemotherapy of rodent malaria. LVIII. Drug combinations to impede the selection of drug resistance, part 2: the new generation - artemesinin or artesunate with long-acting blood schizontocides. Ann. Trop. Med. Parasitol. (2000) 94:23–35.
   Google Scholar
• TRAGER W, JENSEN JB: Human malaria parasites incontinuous culture. Science (1976) 193:673–675.
   PubMed Web of Science ®Google Scholar
• AIKAWA M, SCHWARTZ A, UNI S, NUSSENZWEIG R, HOLLINGDALE M: Ultrastructure of in vitro cultured exoerythrocytic stage of Plasmodium berghei in a hepatoma cell line. Am. J. Trop. Med. Hyg. (1984) 33:792–799.
   PubMed Web of Science ®Google Scholar
• SLATER AFG: Chloroquine: mechanism of drug action and resistance in Plasmodium falciparum. Pharmacol Ther. (1993) 57:203–235.
   PubMed Web of Science ®Google Scholar
• FOLEY M, TILLEY L: Quinoline antimalarials: mechanisms of action and resistance and prospects for new agents. Pharmacol. Ther. (1998) 79:55–87.
   PubMed Web of Science ®Google Scholar
• EGAN TJ, MARQUES HM: The role of haem in the activity of chloroquine and related antimalarial drugs. Coord. Chem. Rev. (1999) 1 90–1 92:493–517.
   Google Scholar
• PARKER FS, IRVIN JL: The interaction of chloroquine with nucleic acids and nucleoproteins. J Biol. Chem. (1952) 199:897–909.
   PubMed Web of Science ®Google Scholar
• SURIOLA N, PADMANABAN G: Chloroquine inhibits haem-dependent protein synthesis in Plasmodium falciparum. Proc. Natl. Acad. Sci. USA (1991) 88:4786–4790.
   PubMed Web of Science ®Google Scholar
• KONIGK E, MIRTSCH S, PUTFARKEN B, ABDEL-RASOUL S:Plasmodium chabaudi-infection of mice: effects of chloroquine and mefloquine. Inhibition of ornithine decarboxylase activity. Trop. Parasitol. (1981) 32:73–76.
   Google Scholar
• HOMEWOOD CA, WARHURST DC, BAGGALEY VC: Incorporation of radioactive precursors into Plasmo-dium berghei in vitro. Trans. R. Soc. Trop. Med. Hyg. (1971) 65:10.
   Web of Science ®Google Scholar
• SHERMAN IW: The ribosomes of the simian malariaPlasmodium knowlesi. II. A cell-free protein synthe-sising system. Comp. Biochem. Physiol. (1976) 53B:447–450.
   Google Scholar
• KIRBY GC, O'NEILL MJ, PHILLIPSON D, WARHURST DC: In vitrostudies on the mode of action of quassinoids with activity against chloroquine resistant Plasmodium falciparum. Biochem. Pharmacol. (1989) 38:4367–4374.
   PubMed Web of Science ®Google Scholar
• HOMEWOOD CA, WARHURST DC, PETERS W, BAGGALEY VC: Lysosomes, pH and the anti-malarial action of chloroquine. Nature (1972) 235:50–52.
   PubMed Web of Science ®Google Scholar
• JACOBS GH, AIKAWA M, MILHOUS WK, RABBEGE JR: An ultrastructural study of the effects of mefloquine on malaria parasites. Am. J. Trop. Med. Hyg. (1987) 36:9–14.
   PubMed Web of Science ®Google Scholar
• OLLIARO P, CASTELLI F, CALIGARIS S, DRUIHE P, CAROSI G: Ultrastructure of Plasmodium falciparum in vitro. II. Morphological patterns of different quinolines' effects. Microbiologia (1989) 12:15–28.
   Google Scholar
• PETERS W, HOWELLS RE, PORTUS J, ROBINSON BL, THOMAS S, WARHURST DC: The chemotherapy of rodent malaria. XXVII. Studies on mefloquine (WR1 42490). Ann. Trop. Med. Parasitol. (1977) 71:407–418.
   PubMed Web of Science ®Google Scholar
• MACOMBER PB, SPRINZ H, TOUSIMIS AJ: Morphological effects of chloroquine on Plasmodium berghei in mice. Nature (1967) 214:937–939.
   PubMed Web of Science ®Google Scholar
• WARHURST DC, HOCKLEY DJ: Mode of action of chloro-quine on Plasmodium berghei and P. cynomolgi. Nature (1967) 214:935–936.
   PubMed Web of Science ®Google Scholar
• GINSBURG H, KRUGLIAK M: Quinoline-containing antimalarials - mode of action, drug resistance and its reversal. Biochem. Pharmacol. (1992) 43:63-70.© Ashley Publications Ltd. All rights reserved.Exp. Opin. Ther. Patents (2001) 11(2)
   Google Scholar
• GYANG FN, POOLE B, TRAGER W: Peptidases from Plasmodium falciparum cultured in vitro. Ma Biochem. Parasitol. (1982) 5:263–273.
   PubMed Web of Science ®Google Scholar
• KROGSTAD DJ, SCHLESINGER PH, GLUZMAN IY: Antimalarials increase vesicle pH in Plasmodium falciparum.j Cell Biol. (1985) 1 01 :2302–2309.
   Google Scholar
• YAYON A, CABANTCHIK ZI, GINSBURG H: Susceptibility of human malaria parasites to chloroquine is pH dependent. Proc. Natl. Acad. Sci. USA (1985) 82:2784–2788.
   PubMed Web of Science ®Google Scholar
• GINSBURG H, NISSANI E, KRUGLIAK M: Alkalinisation of the food vacuole of malaria parasites by quinoline drugs and alkylamines is not correlated with their antimalarial activity. Biochem. Pharmacol (1989) 38:2645–2654.
   PubMed Web of Science ®Google Scholar
• URSOS LMB, DZEKUNOV SM, ROEPE PD: The effects of chloroquine and verapamil on digestive vacuolar pH of P. falciparum either sensitive or resistant to chloro- quine. Mol Biochem. Parasitol (2000) 110:125–134.
   PubMed Web of Science ®Google Scholar
• ••A study of the effect of chloroquine and verapamil onvacuolar pH in live single parasites.
   Google Scholar
• COHEN SN, PHIFER KO, YIELDING KL: Complex formation between chloroquine and ferrihaemic acid in vitro and its effects on the antimalarial action of chloroquine. Nature (1964) 202:805–806.
   PubMed Web of Science ®Google Scholar
• CHOU AC, CHEVLI R, FITCH CD: Ferriprotoporphyrin IX fulfills the criteria for identification as the chloro-quine receptor of malaria parasites. Biochemistry (1980) 1 9:1543–1549.
   Google Scholar
• MOON RP, TYAS L, CERTA U et al: Expression and characterisation of plasmepsin I from Plasmodium falciparum. Eur.J. Biochem. (1997) 244:552–560.
   PubMedGoogle Scholar
• MUNGTHIN M, BRAY PG, RIDLEY RG, WARD SA: Central role of haemoglobin degradation in mechansims of action of 4-aminoquinolines, quinoline methanols and phenanthrene methanols. Antimicr. Agents Chemother. (1998) 42:2973–2977.
   PubMed Web of Science ®Google Scholar
• ••A study that provides definitive evidence that the activity ofchloroquine is dependent on haemoglobin degradation in the parasite.
   Google Scholar
• BRAY PG, MUNGTHIN M, RIDLEY RG, WARD SA: Access to haematin: the basis of chloroquine resistance. Mol. Pharmacol. (1998) 54:170–179.
   PubMed Web of Science ®Google Scholar
• ••This paper provides a detailed analysis of drug accumula-tion in chloroquine sensitive and resistant parasites and shows that specific, saturable chloroquine binding occurs, which is dependent on haemoglobin degradation in the parasite. Reduced binding occurs in resistant parasites.
   Google Scholar
• BRAY PG, JANNEH 0, RAYNES K, MUNGTHIN M, GINSBURG H, WARD SA: Cellular uptake of chloroquine is dependent on binding to ferriprotoporphyrin IX and is independent of NHE activity in Plasmodium falciparum. J. Cell Biol. (1999) 145:363–376.
   PubMed Web of Science ®Google Scholar
• •A detailed investigation of chloroquine resistance, indicating that resistance results from decreased binding of drug to haematin and not due to decreased activity of a putative chloroquine importer.
   Google Scholar
• DORN A, VIPPAGUNTA SR, MATILE H, JAQUET C, VENNERSTROM JL, RIDLEY RG: An assessment of drug-haematin binding as a mechanism for inhibition of haematin polymerisation by quinoline antimalari-als. Biochem. Pharmacol. (1998) 55:727–736.
   PubMed Web of Science ®Google Scholar
• •A paper indicating a relationship between strength of haematin-drug binding, I3-haematin inhibitory potency and antiplasmodial activity of a series of quinoline drugs.
   Google Scholar
• VIPPAGUNTA SR, DORN A, RIDLEY RG, VENNERSTROM JL: Characterization of chloroquine-haematin mu-oxo dimer binding by isothermal titration calorimetry. Biochim. Biophys. Acta (2000) 1475:133–140.
   PubMed Web of Science ®Google Scholar
• EGAN TJ, MAVUSO WW, ROSS DC, MARQUES HM: Thermodynamic factors controlling the interaction of quinoline antimalarial drugs with ferriprotopor-phyrin IX. J. Inorg. Biochem. (1997) 68:137–145.
   PubMed Web of Science ®Google Scholar
• EGAN TJ, HEMPELMANN E, MAVUSO WW: Characterisa-tion of synthetic 13-haematin and effects of the antima-larial drugs quinidine, halofantrine, desbutylhalo-fantrine and mefloquine on its formation. J. Inorg. Biochem. (1999) 73:101–107.
   PubMedGoogle Scholar
• MOREAU S, PERLY B, CHACHATY C, DELEUZE C: A nuclear magnetic resonance study of the interactions of antimalarial drugs with porphyrins. Biochim. Biophys. Acta (1985) 840:107–116.
   PubMed Web of Science ®Google Scholar
• CONSTANTINIDIS I, SATTERLEE JD: UV-visible andcarbon NNIR studies of chloroquine binding to urohaemin I chloride and uroporphyrin lin aqueous solutions. J. Am. Chem. Soc. (1988) 110:4391–4395.
   Web of Science ®Google Scholar
• ADAMS PA, BERMAN PAM, EGAN TJ, MARSH PJ, SILVER J:The iron-environment in haem and haem-antimalarial complexes of pharmacological interest. J. Inorg. Biochem. (1996) 63:69–77.
   PubMed Web of Science ®Google Scholar
• SUGIOKA Y, SUZUKI M: The chemical basis for theferriprotoporphyrin IX-chloroquine induced lipid peroxidation. Biochim. Biophys. Acta (1991) 1074:19–24.
   PubMed Web of Science ®Google Scholar
• GINSBURG H, FAMIN 0, ZHANG F, KRUGLIAK M: Inhibi-tion of glutathione-dependent degradation of haem by chloroquine and amodiaquine as a possible basis for their antimalarial mode of action. Biochem. Pharmacol (1998) 56:1305–1313.
   PubMed Web of Science ®Google Scholar
• ••This paper presents an alternative hypothesis for the modeof action of quinoline antimalarials, suggesting that binding of drugs to haematin inhibits its detoxification by glutathione-dependent degradation in the cytosol.
   Google Scholar
• LORIA P, MILLERS, FOLEY M, TILLEY L: Inhibition of the peroxidative degradation of haem as the basis of action of chloroquine and other quinoline antimalari-als. Biochem. J. (1999) 339:363–370.
   PubMed Web of Science ®Google Scholar
• ••This paper presents another alternative hypothesis for themode of action of quinoline antimalarials, suggesting that binding of drugs to haematin inhibits its detoxification by peroxide-dependent degradation in the food vacuole.
   Google Scholar
• EGAN TJ, ROSS DC, ADAMS PA: Quinoline anti-malarial drugs inhibit spontaneous formation of 13-haematin (malaria pigment). FEBS Lett. (1994) 352:54–57.
   PubMed Web of Science ®Google Scholar
• •The original paper showing that chloroquine inhibits I3-haematin formation by direct interaction with haematin under synthetic, protein-free conditions.
   Google Scholar
• SULLIVAN DJ, GLUZMAN IY, RUSSELL DG, GOLDBERG DE: On the molecular mechanism of chloroquine's antimalarial action. Proc. Natl. Acad. Sci. USA (1996) 93 :11865–11870.
   PubMed Web of Science ®Google Scholar
• •A paper indicating that I3-haematin formation is inhibited by interaction of haematin-chloroquine complex with the growing pigment crystal (assumed to be a polymer at the time) and showing that this occurs even when initiated with histidine rich protein.
   Google Scholar
• SULLIVAN DJ, MATILE H, RIDLEY RG, GOLDBERG DE: A common mechanism for blockade of haem polymeri-sation by antimalarial quinolines. J. Biol. Chem. (1998) 273:31103–31107.
   PubMed Web of Science ®Google Scholar
• BASILICO N, PAGANI E, MONTI D, OLLIARO P, TARAMELLI D: A microtitre-based method for measuring the haem polymerisation inhibitory activity (HPIA) of antimalarial drugs. J Antimicr. Chemother. (1998) 42:55–60.
   PubMed Web of Science ®Google Scholar
• EGAN TJ, HUNTER R, KASCHULA CH, MARQUES HM, MISPLON A, WALDEN J: Structure-function relation-ships in aminoquinolines: effect of amino and chloro groups on quinoline-haematin complex formation, inhibition of 13-haematin formation and antiplasmo-dial activity. J Med. Chem (2000) 43:283–291.
   PubMed Web of Science ®Google Scholar
• ••A detailed investigation of structure-function relationshipsin chloroquine and establishing minimal structural require-ments for association with haematin, inhibition of I3-haematin formation and antiplasmodial activity.
   Google Scholar
• VIPPAGUNTA SR, DORN A, MATILE H et al.: Structural specificity of chloroquine-haematin binding related to inhibition of haematin polymerisation and parasite growth. J. Med. Chem. (1999) 42:4630–4639.
   PubMed Web of Science ®Google Scholar
• ••A detailed investigation of the effect of quinoline ringsubstituents on the association of quinolines with haematin, their I3-haematin inhibitory potency and antiplasmodial activity. It includes some molecular modeling.
   Google Scholar
• DE D, KROGSTAD FM, COGSWELL FB, KROGSTAD DJ: Amino quinolin es that circumvent resistance in Plasmodium fakiparum in vitro. Am. J Trop. Med. Hyg. (1996) 55:579–583.
   PubMed Web of Science ®Google Scholar
• ••A paper showing that chloroquine analogues with shorter orlonger aminoalkyl side chains are fully active against chloro-quine resistant parasites.
   Google Scholar
• DE D, KROGSTAD FM, BYERS LD, KROGSTAD DJ: Structure-activity relationships for an tiplasmo dial activity among 7-substituted 4-aminoquinolines. Med. Chem. (1998) 41 :4918–4926.
   Web of Science ®Google Scholar
• •A paper showing the effect of replacing the 7-chloro group on chloroquine and chloroquine analogues with other halogens.
   Google Scholar
• O'NEILL PM, WILLOCK DJ, HAWLEY SR, BRAY PG, STORR RC, WARD SA, PARK BK: Synthesis, antimalarial activity and molecular modelling of tebuquine analogues. J Med. Chem (1997) 40:437–448.
   PubMed Web of Science ®Google Scholar
• •A paper establishing the relationship between quinoline accumulation in parasitised red blood cells and antiplasmo-dial activity.
   Google Scholar
• RAYNES KJ, STOCKS PA, O'NEILL PM, PARK BK, WARD SA: New 4-aminoquinoline Mannich base antimalarials. 1. Effect of an alkyl substituent in the 5'-position of the 4t-hydroxyanilino side chain. J Med. Chem. (1999) 42:2747–2751.
   Google Scholar
• ••Novel Mannich base compounds that show activity againstchloroquine resistant parasites and circumvent the toxicity problems of amodiaquine.
   Google Scholar
• KOTECKA BM, BARLIN GB, EDSTEIN MD, RIECKMANN KH: New quinoline di-Mannich base compounds with greater antimalarial activity than chloroquine, amodiaquine or pyronaridine. Antimicr. Agents Chemother. (1997) 41:1369–1374.
   PubMed Web of Science ®Google Scholar
• ••Novel Mannich base compounds related to both amodia-quine and pyronaridine in structure and which circumvent chloroquine resistance and amodiaquine-like toxicity.
   Google Scholar
• BIOT C, GLORIAN G, MACIEJEWSKI LA, BROCARD JS: Synthesis and antimalarial activity in vitro and in vivo of a new ferrocene-chloroquine analogue. J Med. Chem. (1997) 40:3715–3718.
   PubMed Web of Science ®Google Scholar
• CHIBALE K, MOSS JR, BLACKIE M, VAN SCHALKWYK D, SMITH PJ: New amine and urea analogs of ferrochloro-quine: synthesis, antimalarial activity in vitro and electrochemical studies. Tetrahedron Lett. (2000) 41:6231–6235.
   Web of Science ®Google Scholar
• RAYNES K: Bisquinoline antimalarials: their role in malaria chemotherapy. Int. J. Parasitol. (1999) 29:367–379.
   PubMed Web of Science ®Google Scholar
• RAYNES K, GALATIS D, COWMAN AF, TILLEY L, DEADY LW: Synthesis and activity of some antimalarial bisqui-nolines. J Med. Chem. (1995) 38:204–206.
   PubMedGoogle Scholar
• OLIVEIRA MF, SILVA JR, DANSA-PETRETSKI M et al: Haem detoxification by an insect. Nature (1999) 400:517–518.
   PubMed Web of Science ®Google Scholar
• OLIVEIRA MF, SILVA JR, DANSA-PETRETSKI M et al.: Haemozoin formation in the midg-ut of the blood sucking insect Rhodnius prolixus. FEBS Lett. (2000) 477:95–98.
   PubMed Web of Science ®Google Scholar
• KARLE JM, KARLE IL, GERENA L, MILHOUS WK: Stereo-chemical evaluation of the relative activities of the cinchona alkaloids against Plasmodium falciparum. Antimicr. Agents Chemother. (1992) 36:1538–1544.
   PubMed Web of Science ®Google Scholar
• CONSTANTINIDIS I, SATTERLEE JD: UV-visible and carbon NMRstudies of quinine binding to urohaemin I chloride and uroporphyrin I in aqueous solutions. J Am. Chem. Soc. (1988) 110:927–932.
   Web of Science ®Google Scholar
• MARQUES HM, VOSTER K, EGAN TJ: The interaction of the haem-octapeptide, N-acetylmicroperoxidase-8 with antimalarial drugs: solution studies and modelling by molecular mechanics methods. J. Inorg. Biochem. (1996) 64:7–23.
   PubMed Web of Science ®Google Scholar
• SCHLESINGER PH, KROGSTAD DJ, HERWALDT BL: Antimalarial agents: mechanism of action. Antimicr. Agents Chemother. (1988) 32:793–798.
   PubMed Web of Science ®Google Scholar
• FITCH CD: Chloroquine resistance in malaria: a deficiency of chloroquine binding. Proc. Natl. Acad. Sci. USA (1969) 64:1181–1187.
   PubMed Web of Science ®Google Scholar
• FITCH CD, CHEVLI R, GONZALEZ Y: Chloroquine-resistant Plasmodium falciparum: effect of substrate on chloroquine and amodiaquin accumulation.Antimicr. Agents Chemother. (1974) 6:757–762.
   PubMed Web of Science ®Google Scholar
• SALIBA KJ, FOLB PI, SMITH PJ: Role for the Plasmodium falciparum digestive vacuole in chloroquine resistance. Biochem. Pharmacol. (1998) 56:313–320.
   PubMed Web of Science ®Google Scholar
• •The first paper to provide direct evidence for reduced drug uptake into the food vacuole in chloroquine resistant parasites.
   Google Scholar
• MARTIN SK, ODUOLA AMJ, MILHOUS WK: Reversal of chloroquine resistance in Plasmodium falciparum by verapamil. Science (1987) 235:899–901.
   PubMed Web of Science ®Google Scholar
• FOOTE SJ, THOMPSON JK, COWMAN AF, KEMP DJ: Amplification of the multidrug resistance gene in some chloroquine-resistant isolates of P. falciparum. Cell (1989) 57:921–930.
   Web of Science ®Google Scholar
• FOOTE SJ, KYLE DE, MARTIN RK eta].: Several alleles of the multidrug-resistance gene are closely linked to chloroquine resistance in Plasmodium falciparum. Nature (1990) 345:255–258.
   Google Scholar
• BASCO LK, LE BRAS J, RHOADES Z, WILSON CM: Analysis of pfmdrl and drug susceptibility in fresh isolates of Plasmodium falciparum from subsaharan Africa. Mol. Biochem. Parasitol. (1995) 74:157–166.
   PubMed Web of Science ®Google Scholar
• COX SINGH J, SINGH B, ALIAS A, ABDULLAH MS: Assess-ment of the association between three pfmdrl point mutations and chloroquine resistance in vitro of Malaysian Plasmodium falciparum isolates. Trans. R. Soc. Trop. Med. Hyg. (1995) 89:436–437.
   PubMed Web of Science ®Google Scholar
• ADAGU IS, DIAS F, PINHEIRO L, ROMBO L, DO ROSARIO V, WARHURST DC: Guinea Bissau: association of chloroquine resistance of Plasmodium falciparum with the Tyr 86 allele of the multidrug resistance gene pfmdrl. Trans. R. Soc. Trop. Med. Hyg. (1996) 90:90–91.
   PubMed Web of Science ®Google Scholar
• DURAISINGH M, DRAKELEY CJ, MULLER 0 et al.: Selection for the tyrosine-86 mutation of the pfmdrl gene of Plasmodium falciparum by chloroquine and amodiaquine. Parasitology (1997) 114:205–211.
   Google Scholar
• WELLEMS TE, PANTON LJ, GLUZMAN IY et al: Chloro-quine resistance not linked to mdr-like genes in a Plasmodium falciparum cross. Nature (1990) 345:253–255.
   PubMed Web of Science ®Google Scholar
• •This paper provides evidence that the parasite multi-drug resistance gene is not directly responsible for chloroquine resistance.
   Google Scholar
• COWMAN AF, GALATIS D, THOMPSON JK: Selection for mefloquine resistance in Plasmodium falciparum is linked to amplification of the pfmdrl gene and cross-resistance to halofantrine and quinine. Proc. Natl. Acad. ScL USA (1994) 91:1143–1147.
   PubMed Web of Science ®Google Scholar
• PEEL SA, BRIGHT P, YOUNT B, HANDY J, BARIC RS: A strong association between mefloquine and halofan-trine resistance and amplification, overexpression and mutation in the P-glycoprotein gene homologue (pfmdr) of Plasmodium falciparum in vitro. Am. J. Trop. Med. Hyg. (1994) 51:648–658.
   PubMed Web of Science ®Google Scholar
• WILSON CM, VOLKMAN SK, THAITHONG S et al: Amplifi-cation of pfmdrl associated with mefloquine and halofantrine resistance in Plasmodium falciparum from Thailand. Mol. Biochem. Parasitol. (1993) 57:151–160.
   PubMed Web of Science ®Google Scholar
• DURAISINGH MT, JONES P, SAMBOU I, VON SEIDLEIN L, PINDER M, WARHURST DC: The tyrosine-86 allele of the pfmdrl gene of Plasmodium falciparum is associated with increased sensitivity to the anti-malarials mefloquine and artemesinin. Mol. Biochem. Parasitol (2000) 108:13–23.
   PubMed Web of Science ®Google Scholar
• FIDOCK DA, NOMURA T, COOPER RA, SU X-Z, TALLEY AK, WELLEMS TE: Allelic modifications of the cg2 and cgl genes do not alter the chloroquine response of drug-resistant Plasmodium falciparum. Mol. Biochem. Parasitol (2000) 110:1–10.
   PubMed Web of Science ®Google Scholar
• ••Evidence that the cgl and cg2 genes are not responsible forchloroquine resistance.
   Google Scholar
• FIDOCK DA, NOMURA T, TALLEY AK eta].: Mutations in the P. falciparum digestive vacuole transmembrane protein PfCRT and evidence for their role in chloro-quine resistance. Mol Cell (2000) 6:861–871.
   Google Scholar
• ••A detailed investigation of the relationship between thetransmembrane protein PfCRT and chloroquine resistance. Strong evidence is presented that indicates that specific mutations in this protein are the cause of chloroquine resistance.
   Google Scholar
• KROGSTAD DJ, GLUZMAN IY, KYLE DE et al.: Efflux of chloroquine from Plasmodium falciparum: mechanism of chloroquine resistance. Science (1987) 238:1283–1285.
   PubMed Web of Science ®Google Scholar
• SANCHEZ CP, WeNSCH S, LANZER M: Identification of a chloroquine importer in Plasmodium falciparum: differences in import kinetics are genetically linked with a chloroquine-resistant phenotype. J Biol. Chem. (1997) 272:2652–2658.
   PubMed Web of Science ®Google Scholar
• WÜNSCH S, SANCHEZ CP, GEKLE M, GROSSE-WORTMANN L, WIESNER J, LANZER M: Differential stimulation of the Na+7I1+ exchanger determines chloroquine uptake in Plasmodium falciparum. J. Cell. Biol. (1998) 140:335–345.
   PubMed Web of Science ®Google Scholar
• MARTINEY JA, FERRER AS, CERAMI A, DZEKUNOV SM, ROEPE PD: Chloroquine uptake, altered partitioning and the basis of drug resistance: evidence for chloride-dependent ionic regulation. Novartis Found. Symp. (1999) 226:265–280.
   PubMedGoogle Scholar
• DZEKUNOV SM, URSOS LMB, ROEPE PD: Digestive vacuolar pH of intact intraerythrocytic P. falciparum either sensitive or resistant to chloroquine. Mol. Biochem. Parasitol (2000) 110:107–124.
   PubMed Web of Science ®Google Scholar
• ••This paper reports the vacuolar pH of live single parasitecells and demonstrates that vacuolar pH is lower in chloro-quine resistant cells than in chloroquine sensitive cells. Evidence is presented that haematin binds less chloroquine at the lower pH as a result of aggregation, possibly giving rise to resistance.
   Google Scholar
• NAVARRO M, PÉREZ H, SANCHEZ-DELGADO RA: Toward a novel metal-based chemotherapy against tropical diseases. 3. Synthesis and antimalarial activity in vitro© Ashley Publications Ltd. All rights reserved.Exp. Opin. Ther. Patents (2001) 11(2) and in vivo of the new gold-chloroquine complex [Au (PPh3)(CQ)]PF6. J. Med. Chem. (1997) 40:1937–1939.
   Google Scholar
• WHITE NJ: Antimalarial drug resistance and combina-tion chemotherapy. Philos. Trans. R. Soc. Lond. (1999) B29:739–749.
   Google Scholar
• WHITE NJ: Delaying antimalarial drug resistance with combination chemotherapy. Parassitologia (1999) 41:301–308.
   PubMedGoogle Scholar
• PRICE RN, NOSTEN F, LUXEMBURGER C, VAN VUGT MLP, CHONGSUPHAJAISIDDHI T, WHITE NJ: Ar tesu-nate/mefloquine treatment of multi-drug resistant falcip arum malaria. Trans. R. Soc. Trop. Med. Hyg. (1997) 91:574–577.
   PubMed Web of Science ®Google Scholar
• MCINTOSH HM, GREENWOOD BM: Chloroquine or amodiaquine combined with sulfadoxine-pyrimethamine as a treatment for uncomplicated malaria - a systematic review. Ann. Trop. Med. Parasitol. (1998) 92:265–270.
   PubMed Web of Science ®Google Scholar
• MCINTOSH HM: Chloroquine or amodiaquine combined with sulfadoxine-pyrimethamine for treating uncomplicated malaria. Cochrane Database SysL Rev. (2000) CD000386.
   Google Scholar
• PETERS W: The chemotherapy of rodent malaria. LVH. Drug combinations to impede the selection of drug resistance, part 1. Which model is appropriate? Ann. Trop. Med. Parasitol. (1999) 93:569–587.
   Google Scholar
• RIDLEY RG, HOFHEINZ W, MATILE H et al.: 4-Arninoquinoline analogues of chloroquine with shortened side-chains retain activity against chloro-quine resistant Plasmodium fakiparum. Antimicr. Agents Chemother. (1996) 40:1846–1854.
   PubMed Web of Science ®Google Scholar
• GOMES M, OLLIARO P, FOLB PI: What role can public health institutions play in drug development for the poor? A case study of artesunate. Med. Trop. (Mars) (1998) 58 (Suppl. 3):97–100.
   Google Scholar
• •A review describing a novel approach to antimalarial drug development for the poor.
   Google Scholar